These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 2855613

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Relative efficacy of tazobactam, sulbactam and clavulanic acid in enhancing the potency of ampicillin against clinical isolates of Enterobacteriaceae.
    Pfaller M, Barry A, Fuchs P, Gerlach E, Hardy D, McLaughlin J.
    Eur J Clin Microbiol Infect Dis; 1993 Mar; 12(3):200-5. PubMed ID: 8389705
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. [beta-Lactamase-inhibitor combinations].
    Nakano R, Okamoto R.
    Nihon Rinsho; 2003 Mar; 61 Suppl 3():221-6. PubMed ID: 12717975
    [No Abstract] [Full Text] [Related]

  • 29. Antibacterial characteristics of YTR 830, a sulfone beta-lactamase inhibitor, compared with those of clavulanic acid and sulbactam.
    Moosdeen F, Williams JD, Yamabe S.
    Antimicrob Agents Chemother; 1988 Jun; 32(6):925-7. PubMed ID: 2843088
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Clinical application of beta-lactamase inhibitors on urinary tract infections].
    Ohkawa M.
    Nihon Rinsho; 1986 Dec; 44(12):2573-7. PubMed ID: 3029463
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Comparative in vitro inhibitory activities of novel beta-lactam compounds against multiresistant beta-lactamase producing Staphylococcus aureus.
    Ray B, Panja K, Bal M.
    Indian J Med Res; 1986 May; 83():453-7. PubMed ID: 3015791
    [No Abstract] [Full Text] [Related]

  • 36. Beta-lactamase inhibition by acetylmethylene penicillanic acid compared to that of clavulanate and sulbactam.
    Chin NX, McElrath MJ, Neu HC.
    Chemotherapy; 1988 May; 34(4):318-25. PubMed ID: 2850139
    [Abstract] [Full Text] [Related]

  • 37. Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin.
    Aronoff SC, Jacobs MR, Johenning S, Yamabe S.
    Antimicrob Agents Chemother; 1984 Oct; 26(4):580-2. PubMed ID: 6097169
    [Abstract] [Full Text] [Related]

  • 38. Antimicrobial activity of cefoperazone with clavulanic acid or sulbactam against Enterobacteriaceae.
    Nagy E, Hajdu E, Földes J.
    J Antimicrob Chemother; 1990 Apr; 25(4):701-3. PubMed ID: 2351631
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.